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In the article entitled SCOMP Is Superior to Degenerated
Oligonucleotide Primed-Polymerase Chain Reaction for
Global Amplification of Minute Amounts of DNA from Micro-
dissected Archival Tissue Samples (Volume 161, pages
43–51 of the July 2002 issue), the primers listed in Table
2 for D5S500 were incorrect. The correct primer se-
quences are: 5-GTATCGGTGAAATGCAACTA-3 and
5-CTTTTTACATTTTTGGTACCTTG-3.
In the article entitled Abnormal Uterine Bleeding during
Progestin-Only Contraception May Result from Free Radi-
cal-Induced Alterations in Angiopoietin Expression (Volume
161, pages 979–986 of the September 2002 issue), the
grant information was incorrect. The correct grant informa-
tion is National Institutes of Health grant RO1 HD33937–06.
In the article entitled Nitration of Tau Protein Is Linked to
Neurodegeneration in Tauopathies (Volume 163, pages
1021–1031 of the September 2003 issue), Figures 3, 4,
and 5 should have appeared in color. The corrected
article, including color figures, appears at http://ajp.amj-
pathol.org/cgi/content/full/163/3/1021.
In the article entitled Expression of Calcium-Binding Pro-
teins MRP8 and MRP14 in Inflammatory Muscle Diseases
(Volume 163, pages 947–956 of the September 2003 is-
sue), the authors’ affiliations should have read as follows:
Stephan Seeliger,*† Thomas Vogl,* Ingo Hubert En-
gels,* J. Michael Schro¨der,‡ Clemens Sorg,* Cord Sun-
derko¨tter,*§ and Johannes Roth*†
From the Institute of Experimental Dermatology,* the De-
partment of Pediatrics,† University of Mu¨nster, Mu¨nster; the
Department of Neuropathology,‡ University Hospital, RWTH-
Aachen, Aachen; and the Department of Dermatology and Al-
lergy,§ University of Ulm, Ulm, Germany
In the article entitled Relevance of Nuclear and Cytoplas-
mic von Hippel Lindau Protein Expression for Renal Carci-
noma Progression (Volume 163, pages 1013–1020 of the
September 2003 issue), the second author’s name was
incorrectly spelled. The correct spelling for this author’s
name is Alexander Hergovich.
In the article entitled Up-Regulation of Phosphorylated/
Activated p70 S6 Kinase and Its Relationship to Neurofibril-
lary Pathology in Alzheimer’s Disease (Volume 163, pages
591–607 of the August 2003 issue), several errors ap-
peared in the print edition. The seventh author’s name
should have read Inge Grundke-Iqbal. Throughout the
article, references to “R134”, “134 days” and “R134
days” should have read “R134 days”. Other minor errors
have also been noted. Please refer to http://ajp.
amjpathol.org/cgi/content/full/163/2/591/DC1 for the
corrected pdf of this article.
In the article entitled Detection of Oncofetal H19 RNA in
Rheumatoid Arthritis Synovial Tissue (Volume 163, pages
901–911 of the September 2003 issue), the last sentence
of the third paragraph on page 903 should have read as
follows: “Alternatively, the housekeeping gene -actin
(downstream primer: GTGCGACGAAGACGAGACC; up-
stream primer: CAGAGCCG AGACACCACG; resulting
fragment length, 230 bp) was used as an internal standard
(conditions: initial denaturation at 93°C for 3 minutes, fol-
lowed by a total of 28 to 34 cycles; denaturation at 93°C for
45 seconds, annealing at 62°C for 45 seconds, and exten-
sion at 72°C for 30 seconds).” In the legend for Figure 5, the
symbol § denotes P 0.05 in comparison with RA-SFBs; (§)
denotes P  0.10 in comparison with RA-SFBs. In the
legend for Figure 6, the symbol  denotes P  0.05 in
comparison with the respective stimulus without inhibitor.
Additionally in this article, Table 1 appeared incorrectly. The
correct table appears here (see Table 1).
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Table 1. Clinical Characteristics of the Patients at the Time of Synovectomy/Sampling
Patients (total)
Gender
(m/f) Age (yrs)
Disease
duration (yrs) RF (/)
ESR
(mm/1h)
CRP*
(mg/l)
# of
ARA-criteria
(RA)
Concomitant
medication (n)
Rheumatoid arthritis (RA)
26 9/17 63.2  2.0 14.6  2.5 24/2 45.0  5.3 25.9  4.0 4.9  0.2 MTX (12)
(n.d.5) Prednis. (18)
Sulfas. (4)
Chloroquin (1)
Leflunomide (3)
NSAIDs (21)
Osteoarthritis
25 4/21 68.4  1.8 4.7  0.5 2/19 18.6  3.9 4.6  1.1 0.3  0.1 Prednis. (2)
(n.d.4) (n.d.2) (n.d.1) MTX (1)
NSAIDs (14)
none (10)
Other arthritides
EB32/ReA m 43 8  60 8.5 1 none
EB36/ReA f 31 0.13  50 63.8 0 NSAIDs,
Doxycyclin
Joint trauma
7 3/4 31.9  7.6 0.6  0.4 n.d. n.d. n.d. 0.0  0.0 L-Thyroxin (1)
Nifedipin (1)
Propanolol (1)
none (5)
Normals
8 4/4 51.8  6.9 0.0  0.0 n.d. n.d. n.d. 0.0  0.0 none (8)
Abbreviations are defined as follows: m, male; f, female; yrs, years; RF, rheumatoid factor; /, positive/negative; ESR, erythrocyte sedimentation
rate (mm); CRP, C-reactive protein; *, normal range:  5 mg/l; ARA, American Rheumatism Association (now American College of Rheumatology); n.d.,
not determined; RA, rheumatoid arthritis; ReA, reactive arthritis; MTX, Methotrexate; Prednis., Prednisolone; Sulfas., Sulfasalazine; NSAIDs, non-
steroidal anti-inflammatory drugs.
For the parameters age, disease duration, ESR, CRP, and # of ARA-Criteria (RA) means  SEM are given; for the remaining parameters n numbers
are provided.
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